Analysts See $-1.05 EPS for Prothena Corporation plc (PRTA)

October 13, 2018 - By Ruchi Gupta

Prothena Corporation plc (NASDAQ:PRTA) LogoInvestors sentiment decreased to 0.86 in Q2 2018. Its down 0.03, from 0.89 in 2018Q1. It turned negative, as 31 investors sold Prothena Corporation plc shares while 28 reduced holdings. 20 funds opened positions while 31 raised stakes. 29.12 million shares or 2.41% less from 29.85 million shares in 2018Q1 were reported.
Price Mngmt reported 0.34% of its portfolio in Prothena Corporation plc (NASDAQ:PRTA). Voya Lc has 16,988 shares. Dekabank Deutsche Girozentrale stated it has 15,850 shares or 0% of all its holdings. Comml Bank Of New York Mellon Corp invested in 188,095 shares or 0% of the stock. Jane Street Ltd Liability owns 10,417 shares. Bogle Invest Limited Partnership De stated it has 20,304 shares or 0.02% of all its holdings. Envestnet Asset Mgmt holds 0% or 53 shares. Senzar Asset Mngmt Limited Liability Company invested in 17,090 shares. Northern stated it has 461,279 shares or 0% of all its holdings. Manufacturers Life Ins The reported 30,004 shares or 0% of all its holdings. Hap Trading Llc stated it has 0.09% in Prothena Corporation plc (NASDAQ:PRTA). Vanguard Group Inc invested in 0% or 1.07M shares. 10,397 are owned by Focused Wealth Inc. Trust Department Mb Fincl Bank N A reported 24 shares or 0% of all its holdings. Invesco has 33,443 shares.

Analysts expect Prothena Corporation plc (NASDAQ:PRTA) to report $-1.05 EPS on November, 6.They anticipate $0.32 EPS change or 23.36 % from last quarter’s $-1.37 EPS. After having $-0.98 EPS previously, Prothena Corporation plc’s analysts see 7.14 % EPS growth. The stock increased 1.46% or $0.18 during the last trading session, reaching $12.49. About 264,537 shares traded. Prothena Corporation plc (NASDAQ:PRTA) has declined 77.78% since October 14, 2017 and is downtrending. It has underperformed by 93.40% the S&P500.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Coverage

Among 9 analysts covering Prothena Corp (NASDAQ:PRTA), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Prothena Corp had 11 analyst reports since April 23, 2018 according to SRatingsIntel. The stock of Prothena Corporation plc (NASDAQ:PRTA) has “Buy” rating given on Tuesday, April 24 by Deutsche Bank. On Tuesday, April 24 the stock rating was maintained by Cantor Fitzgerald with “Overweight”. The rating was downgraded by RBC Capital Markets on Monday, April 23 to “Hold”. The firm has “Hold” rating by Jefferies given on Monday, April 23. The firm has “Hold” rating by Barclays Capital given on Monday, April 23. On Tuesday, April 24 the stock rating was downgraded by BTIG Research to “Neutral”. Evercore downgraded it to “In-Line” rating and $12 target in Monday, April 23 report. Nomura maintained it with “Buy” rating and $19 target in Tuesday, April 24 report. Oppenheimer downgraded Prothena Corporation plc (NASDAQ:PRTA) on Monday, April 23 to “Hold” rating. The stock of Prothena Corporation plc (NASDAQ:PRTA) earned “Overweight” rating by Cantor Fitzgerald on Friday, June 15.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The company has market cap of $497.56 million. It is developing antibody product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson??s disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. It currently has negative earnings. The firm has a license, development, and commercialization agreement with F.

Prothena Corporation plc (NASDAQ:PRTA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>